Hormone Replacement Therapy Over 60: A Balanced Guide

Dr. Shweta Patel, MD, FACOG

Board-certified OB/GYN • U.S. Navy veteran (13 years) • Author, The Book of Hormones • Founder, Gaya Wellness

Published July 31, 2025 • Updated May 3, 2026

If you are over 60 and trying to decide whether hormone replacement therapy belongs in your life, you probably do not need another generic benefits list. You need a framework. You need to know which questions separate thoughtful medical care from fear, hype, and refill inertia.

I see three common problems. One woman is told she is “too old” for any hormone conversation, so her sleep, hot flashes, vaginal pain, and urinary symptoms are dismissed. Another is sold hormones as anti-aging medicine with no serious review of stroke risk, clot history, breast imaging, bleeding, blood pressure, uterus status, or dose. A third started hormones years ago and has had the same prescription renewed without anyone asking whether the plan still fits.

All three women deserve better. Hormone therapy after 60 is not automatically wrong, but it is also not casual. The decision should be structured, individualized, and revisited.

Start With the Actual Decision

The first question is not, “Is HRT good or bad?” The first question is, “Which decision are we making?” Starting systemic estrogen for the first time at 64 is different from continuing a low-dose patch that began at 52. Treating painful sex with low-dose vaginal estrogen is different from taking oral estrogen for hot flashes. Adjusting progesterone in a woman with a uterus is different from discussing estrogen alone after hysterectomy.

When the decision is unclear, risk counseling becomes muddy. A woman may be frightened away from local vaginal treatment because she heard a warning that really applied to systemic therapy. Or she may be pushed toward systemic treatment when her main issue is vaginal tissue health, urinary discomfort, or pelvic pain.

At Gaya, I start by naming the decision: continue, start, stop, taper, switch route, lower dose, add endometrial protection, treat locally, or choose a nonhormonal option. That one step prevents a lot of bad medicine.

Use Timing as a Risk Filter, Not a Wall

The 2022 hormone therapy position statement from The North American Menopause Society gives one of the clearest timing frameworks. For healthy women younger than 60 or within 10 years of menopause, the benefit-risk ratio is generally more favorable for bothersome vasomotor symptoms and prevention of bone loss in appropriate candidates. For women who initiate hormone therapy after age 60 or more than 10 years from menopause, the benefit-risk ratio is less favorable because absolute risks of coronary heart disease, stroke, venous thromboembolism, and dementia are higher.

That statement should create caution, not panic. It does not say every woman must stop at 60. In fact, NAMS also states that hormone therapy does not need to be routinely discontinued after age 60 or 65 when a woman has persistent symptoms or other individualized reasons for use.

Timing is a filter. It tells me how hard I need to scrutinize the reason for treatment, cardiovascular risk, clot risk, cognitive risk, route, dose, and alternatives. It does not replace clinical judgment.

Separate Starting From Continuing

If a woman is 62 and has been stable on an appropriate plan since early menopause, I do not automatically pull treatment because a birthday arrived. I ask whether the original indication still exists, whether symptoms return when she lowers the dose, whether her screening is current, and whether her route and progesterone plan still make sense.

If a woman is 66 and wants to start systemic hormone therapy for the first time after 15 years without a period, I slow the conversation down. That does not mean I dismiss her symptoms. It means the threshold for systemic exposure is higher. We review blood pressure, lipids, A1c, smoking, migraine aura, prior clot, stroke, heart attack, breast cancer history, abnormal bleeding, liver disease, medications, and family history.

This distinction matters because women are often given the wrong answer to the wrong scenario. Continuing with review is not the same as continuing forever. Starting late is not the same as being forbidden. The clinical question is whether the expected benefit is strong enough, the contraindications are absent, and the plan can be monitored responsibly.

Define the Treatment Goal Before Choosing the Tool

Hormones should not be prescribed as a vague promise to feel younger. The goal needs to be specific enough to measure. Are we treating hot flashes that wake you five times a night? Night sweats that impair work? Vaginal dryness and pain with intimacy? Recurrent urinary discomfort? Bone loss when other therapies are not a good fit? Sleep disruption clearly driven by vasomotor symptoms?

Once the goal is specific, the tool becomes clearer. Whole-body symptoms may lead to a systemic hormone discussion. Vaginal and urinary symptoms may be better addressed with local therapy. Bone loss may require a broader bone plan. Weight gain may require metabolic care, not just estrogen. Low libido may require a separate sexual health evaluation rather than a reflex testosterone prescription.

The Mayo Clinic frames this well: starting hormone therapy at age 60 or older, or more than 10 years since menopause, increases the risk of serious complications. That risk statement belongs in the room. So does the reality that untreated symptoms can damage sleep, relationships, mood, sexual health, and function. A good plan respects both.

Choose Route and Dose Deliberately

“HRT” is too broad a word to make a safe decision. Oral estrogen, transdermal estradiol, vaginal estrogen, compounded creams, pellets, progesterone capsules, synthetic progestins, and testosterone are different exposures. The route and dose can change the risk conversation.

Oral estrogen passes through the liver first, which can influence clotting factors and triglycerides. Transdermal estradiol, such as a patch, gel, or spray, avoids that first-pass liver effect and is often part of a more conservative systemic strategy in appropriately selected women. That does not make it risk-free. It makes the route medically relevant.

Dose matters just as much. I want the lowest effective dose for a defined clinical goal. Not a dose so low that a woman remains miserable, and not a dose pushed higher because someone is chasing youthful lab levels. After 60, adjustability is part of safety. That is one reason I am cautious with pellets: if side effects, bleeding, breast tenderness, mood changes, acne, hair changes, or concerning levels appear, I want the ability to change course quickly.

Uterus status also changes the plan. If you still have a uterus and use systemic estrogen, you usually need progesterone or another endometrial-protective strategy. If you have had a hysterectomy, progesterone may not be needed for uterine protection. Your surgical history is not a side note. It is safety data.

Know the Red Flags Before You Say Yes

Some histories make systemic hormone therapy inappropriate or much more cautious. I want to know about unexplained vaginal bleeding, prior estrogen-sensitive breast cancer, prior stroke, heart attack, pulmonary embolism, deep vein thrombosis, high-risk clotting disorders, active liver disease, uncontrolled blood pressure, migraine with aura, smoking, and complex cardiovascular risk.

The American College of Obstetricians and Gynecologists describes systemic estrogen as the best treatment for hot flashes and night sweats, while also emphasizing individualized risk and recommending FDA-approved hormone therapy over compounded hormone therapy. That matters because “custom,” “natural,” and “bioidentical” are not substitutes for dose reliability, safety labeling, and medical monitoring.

Red flags do not mean a woman is abandoned. Nonhormonal hot flash medications, sleep treatment, blood pressure control, lipid management, pelvic floor therapy, vaginal moisturizers, local vaginal therapy when appropriate, bone-specific medication, and sexual health treatment may all belong in the plan. The goal is not to force HRT. The goal is to stop pretending there are only two choices: suffer or take hormones.

Treat Vaginal and Urinary Symptoms Separately

Low-dose vaginal estrogen is its own decision. It is used for genitourinary syndrome of menopause: vaginal dryness, burning, tearing, painful sex, tissue fragility, urinary urgency, and recurrent urinary discomfort. It generally has much lower systemic absorption than pills, patches, gels, or sprays used for whole-body symptoms.

This distinction is especially important after 60. A woman may not be a good candidate for systemic estrogen and still deserve a serious conversation about local tissue treatment. Women with prior estrogen-sensitive cancers need coordination with their oncology team, but age alone should not shut down the discussion.

At Gaya, this may connect to hormone replacement therapy for women, menopause care, vaginal rejuvenation, pelvic health, and sexual medicine. Pain with intimacy is not a personal failure. Recurrent urinary discomfort is not something you should be told to simply tolerate.

What the 2026 FDA Label Changes Mean

In February 2026, the FDA approved labeling changes for six menopausal hormone therapy products to clarify benefit-risk considerations. Those changes included removal of certain boxed-warning language related to cardiovascular disease, breast cancer, and probable dementia from those products.

I see this as a correction away from overly broad fear, not a license for casual prescribing. The update does not erase individual risk. It does not mean every woman over 60 should start systemic HRT. It does not make compounded products equivalent to FDA-approved therapies. It does mean women deserve counseling that reflects current evidence instead of stale panic.

The best hormone conversation over 60 is neither “never” nor “everyone.” It is a structured review: indication, timing, start versus continue, route, dose, uterus status, contraindications, alternatives, monitoring, and patient goals.

How Hormonal Agency™ Builds the Plan

Inside Hormonal Agency™, I do not start with a sales script. I start with the clinical map. What are we treating? When did menopause occur? Was it natural, surgical, or medically induced? Have hormones been used before? What happened when they were stopped? Is the patient using compounded therapy, pellets, oral estrogen, transdermal estrogen, vaginal estrogen, progesterone, testosterone, or supplements?

Then we review the rest of the body: breast screening, bleeding history, uterus status, ovarian status, clot history, cardiovascular risk, blood pressure, lipids, glucose, thyroid context, medications, sleep, mood, libido, weight pattern, and bone health. If weight and insulin resistance are active issues, we may connect hormone care to stubborn weight gain, metabolic health, or Weight Loss Concierge. If the goal is prevention and long-term function, we may connect the plan to Her Longevity.

Some women need systemic HRT. Some need to switch from oral to transdermal. Some need progesterone corrected. Some need vaginal therapy instead of systemic escalation. Some need nonhormonal treatment, bone therapy, sleep apnea evaluation, or cardiometabolic care before hormones are even the main conversation.

What I tell women over 60 is simple: do not accept fear-based care, and do not accept hormone hype. Ask for the framework. Ask what you are treating. Ask why this route, why this dose, why now, what risks matter, and how the plan will be reviewed.

Dr. Shweta Patel, MD, FACOG

Board-certified OB/GYN, U.S. Navy veteran, and founder of Gaya Wellness. Dr. Patel leads physician-managed programs in hormone optimization, menopause hormone therapy, and longevity medicine for women in midlife and beyond.

You have not failed. Your plan did.